Drugs / ART002g1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07353398 | Mar 2026 → Jul 2027 expected | familial hypercholesterolemia | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ART002g1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07353398 ↗ |
| Action | Inhibit | “thereby reducing the circulating levels of PCSK9” NCT07353398 ↗ |
| Modality | CRISPR / gene editing | “ART002g1 uses base editing technology” NCT07353398 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion” NCT07353398 ↗ |
| Target | PCSK9 | “interfere with the expression of the PCSK9 gene” NCT07353398 ↗ |